Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS +0.35%80 Days Payable is 133.23 as of Jun. 2026, which is 12% above its 10-year median of 118.48. GuruFocus rates NSE:ALIVUS with a GF Score™ of 80/100 and a GF Value™ of ₹1,027.03 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 926 Drug Manufacturers companies, Alivus Life Sciences ranks better than 70.73% on this metric.
The historical rank and industry rank for Alivus Life Sciences's Days Payable or its related term are showing as below:
NSE:ALIVUS'
s Days Payable Range Over the Past 10 Years
Min: 84.92 Med: 118.48 Max: 142.3
Current: 135.73
During the past 8 years, Alivus Life Sciences's highest Days Payable was 142.30. The lowest was 84.92. And the median was 118.48.
NSE:ALIVUS's Days Payable is ranked better than 70.73% of 926
companies
in the Drug Manufacturers industry
Industry Median: 89.975
vs NSE:ALIVUS: 135.73
Alivus Life Sciences's Days Payable
increased
from Jun. 2025 (131.77) to Jun. 2026 (133.23).
It may suggest that Alivus Life Sciencesdelayed paying its suppliers.
The historical data trend for Alivus Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alivus Life Sciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Days Payable of 133.23 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alivus Life Sciences and its competitors. This is 12% above median its historical median of 118.48. Over the past decade, Alivus Life Sciences' Days Payable has ranged from 84.92 to 142.30. According to the industry distribution chart, Alivus Life Sciences ranks #271 out of 926 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is Alivus Life Sciences' Days Payable too high?
Alivus Life Sciences' current Days Payable of 133.23 is 12% above median its 10-year median of 118.48. Over the past 10 years, this metric has ranged from a low of 84.92 to a high of 142.30. The Drug Manufacturers industry median Days Payable is 89.98. Alivus Life Sciences' value of 133.23 is 48.1% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #271 out of 926 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alivus Life Sciences has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #271 out of 926 companies for Days Payable. This puts Alivus Life Sciences in the upper half of its industry. The industry median Days Payable is 89.98. Alivus Life Sciences' value of 133.23 is 48.1% above this benchmark. Historically, Alivus Life Sciences' own Days Payable has ranged from 84.92 to 142.30 over the past decade. While the company's 10-year median is 118.48 vs. the industry median of 89.98, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.98, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Days Payable of 133.23 is 48.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Days Payable is 133.23, which is 12% above median its own 10-year median of 118.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,027.03, compared to a current price of ₹1,329.80 — trading 29.5% above its estimated fair value. The current Days Payable is 133.23, which is 12% above median its 10-year median of 118.48 and 48.1% above the Drug Manufacturers industry median of 89.98. Alivus Life Sciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Days Payable is 133.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,329.80 is trading 29.5% above its estimated GF Value™ of ₹1,027.03.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Days Payable: 133.23 (12% above median its 10-year median of 118.48)
GF Value™: ₹1,027.03 vs. price of ₹1,329.80 (29.5% above fair value)
Industry Position: 48.1% above the Drug Manufacturers median (#271 of 926)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
80GF Score
Get the complete analysis for NSE:ALIVUS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
